The devastating earthquakes in Venezuela, the impending rationing of life-saving chemotherapy drugs, and the creeping reliance on artificial intelligence to scout soccer players are not isolated events. They are symptoms of a global system that consistently prioritizes corporate profit and market efficiency over human well-being and community resilience. In Venezuela, the loss of life from two recent earthquakes highlights the deep-seated inequalities that leave marginalized populations vulnerable to natural disasters. Decades of economic sanctions and systemic underinvestment in public infrastructure mean that when the earth shakes, the poorest communities bear the brunt of the destruction, lacking the resilient housing and robust emergency services needed to survive.

This pattern of systemic neglect is even more visible in the healthcare sector, where cancer patients now face the terrifying prospect of chemotherapy rationing. The critical shortage of generic oncology drugs like cisplatin and carboplatin is a direct consequence of a capitalist pharmaceutical model. Because generic drugs are inexpensive and generate low profit margins, major pharmaceutical corporations choose not to invest in their production, preferring instead to channel resources into high-priced specialty drugs that promise massive returns for shareholders. When the drive for profit dictates the supply of life-saving medicine, it is vulnerable patients who pay the ultimate price.

The consolidation of pharmaceutical manufacturing in low-wage countries further exposes the instability of the corporate supply chain. To cut labor costs and maximize profit margins, companies have outsourced production to a handful of massive facilities overseas. When these factories face regulatory shutdowns due to safety violations, the global supply of critical cancer treatments collapses overnight. This leaving hospitals with no choice but to ration care, creating a grim hierarchy where medical professionals must decide whose life is worth saving based on administrative criteria.

This rationing crisis exposes the fundamental immorality of a market-based healthcare system. Access to life-saving treatment should be a basic human right, not a commodity subject to the whims of supply-demand dynamics and corporate corner-cutting. Progressive advocates argue that the only sustainable solution to these recurring drug shortages is to remove life-saving medicine from the private market entirely, establishing public manufacturing facilities that prioritize public health and equitable distribution over corporate profits.